Brepocitinib Overview & RVT-3101 Update

... In Which We Built an Industry-Leading 2023 Catalyst Calendar JPM 2022 Program Catalyst JPM 2023 Expected Timing Program Catalyst Expected Timing RVT-3101 Induction data from Phase 2B trial in ulcerative colitis 1Q 2023 VTAMA (tapinarof) Topline data from Phase 3 1H 2023 VTAMA (tapinarof) trials in atopic dermatitis Topline data from Phase 3 trials in atopic dermatitis 1H 2023 cream cream roivant RVT-3101 Final data including chronic therapy period from Phase 2B trial in ulcerative colitis 1H 2023 IMVT-1402 Initial data from Phase 1 trial Mid 2023 Brepocitinib Topline data from potentially registrational Phase 2B trial in systemic lupus erythematosus 2H 2023 4 For investor audiences only

View entire presentation